These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. Baseline and serial measurements of galectin-3 in patients with heart failure: relationship to prognosis and effect of treatment with valsartan in the Val-HeFT. Anand IS; Rector TS; Kuskowski M; Adourian A; Muntendam P; Cohn JN Eur J Heart Fail; 2013 May; 15(5):511-8. PubMed ID: 23291728 [TBL] [Abstract][Full Text] [Related]
23. Galectin-3 in heart failure: high levels are associated with all-cause mortality. Ueland T; Aukrust P; Broch K; Aakhus S; Skårdal R; Muntendam P; Gullestad L Int J Cardiol; 2011 Aug; 150(3):361-4. PubMed ID: 21641051 [No Abstract] [Full Text] [Related]
24. Galectin-3 testing: validity of a novel automated assay in heart failure patients with reduced ejection fraction. Gruson D; Mancini M; Ahn SA; Rousseau MF Clin Chim Acta; 2014 Feb; 429():189-93. PubMed ID: 24365381 [TBL] [Abstract][Full Text] [Related]
25. Regulation of adverse remodelling by osteopontin in a genetic heart failure model. Psarras S; Mavroidis M; Sanoudou D; Davos CH; Xanthou G; Varela AE; Panoutsakopoulou V; Capetanaki Y Eur Heart J; 2012 Aug; 33(15):1954-63. PubMed ID: 21525025 [TBL] [Abstract][Full Text] [Related]
26. Serum concentrations of galectin-3 in patients with cardiac syndrome X. Bozcali E; Polat V; Aciksari G; Opan S; Bayrak IH; Paker N; Karakaya O Atherosclerosis; 2014 Nov; 237(1):259-63. PubMed ID: 25282685 [TBL] [Abstract][Full Text] [Related]
28. The biomarker plasma galectin-3 in advanced heart failure and survival with mechanical circulatory support devices. Erkilet G; Özpeker C; Böthig D; Kramer F; Röfe D; Bohms B; Morshuis M; Gummert J; Milting H J Heart Lung Transplant; 2013 Feb; 32(2):221-30. PubMed ID: 23352394 [TBL] [Abstract][Full Text] [Related]
29. The role of galectin-3 in heart failure and cardiovascular disease. Zhong X; Qian X; Chen G; Song X Clin Exp Pharmacol Physiol; 2019 Mar; 46(3):197-203. PubMed ID: 30372548 [TBL] [Abstract][Full Text] [Related]
30. Renal function largely influences Galectin-3 prognostic value in heart failure. Zamora E; Lupón J; de Antonio M; Galán A; Domingo M; Urrutia A; Troya M; Bayes-Genis A Int J Cardiol; 2014 Nov; 177(1):171-7. PubMed ID: 25499371 [TBL] [Abstract][Full Text] [Related]
31. Short-term Serial Measurement of Galectin-3 in Hospitalized Patients With Acute Heart Failure. Sánchez-Serna J; Pérez-Martínez MT; Asensio-López MC; Casas T; Noguera JA; Pascual-Figal DA Rev Esp Cardiol (Engl Ed); 2018 May; 71(5):401-402. PubMed ID: 28473265 [No Abstract] [Full Text] [Related]
32. The regulation of inflammation by galectin-3. Henderson NC; Sethi T Immunol Rev; 2009 Jul; 230(1):160-71. PubMed ID: 19594635 [TBL] [Abstract][Full Text] [Related]
33. Newer biomarkers in heart failure. Gupta S; Drazner MH; de Lemos JA Heart Fail Clin; 2009 Oct; 5(4):579-88. PubMed ID: 19631181 [TBL] [Abstract][Full Text] [Related]
34. Serial galectin-3 for the monitoring of optimally treated stable chronic heart failure: A pilot study. Piper SE; de Courcey J; Sherwood RA; Amin-Youssef GF; McDonagh TA Int J Cardiol; 2016 Mar; 207():279-81. PubMed ID: 26808993 [No Abstract] [Full Text] [Related]
35. Galectin 3 in heart failure. Wiwanitkit V Clin Res Cardiol; 2010 Aug; 99(8):527; author reply 529. PubMed ID: 20372914 [No Abstract] [Full Text] [Related]
36. Prognostic value of plasma galectin-3 levels in patients with coronary heart disease and chronic heart failure. Yu X; Sun Y; Zhao Y; Zhang W; Yang Z; Gao Y; Cai H; Li Y; Wang Q; Bian B; Nie J Int Heart J; 2015 May; 56(3):314-8. PubMed ID: 25902879 [TBL] [Abstract][Full Text] [Related]
37. Usefulness of a combination of monocyte chemoattractant protein-1, galectin-3, and N-terminal probrain natriuretic peptide to predict cardiovascular events in patients with coronary artery disease. Tuñón J; Blanco-Colio L; Cristóbal C; Tarín N; Higueras J; Huelmos A; Alonso J; Egido J; Asensio D; Lorenzo Ó; Mahíllo-Fernández I; Rodríguez-Artalejo F; Farré J; Martín-Ventura JL; López-Bescós L Am J Cardiol; 2014 Feb; 113(3):434-40. PubMed ID: 24295549 [TBL] [Abstract][Full Text] [Related]
38. Galectin-3 and mineralocorticoid receptor antagonist use in patients with chronic heart failure due to left ventricular systolic dysfunction. Gandhi PU; Motiwala SR; Belcher AM; Gaggin HK; Weiner RB; Baggish AL; Fiuzat M; Brunner-La Rocca HP; Januzzi JL Am Heart J; 2015 Mar; 169(3):404-411.e3. PubMed ID: 25728731 [TBL] [Abstract][Full Text] [Related]
39. Galectin-3 in heart failure: more answers or more questions? Ahmad T; Felker GM J Am Heart Assoc; 2012 Oct; 1(5):e004374. PubMed ID: 23316305 [No Abstract] [Full Text] [Related]
40. The predictive value of galectin-3 for mortality and cardiovascular events in the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA). Gullestad L; Ueland T; Kjekshus J; Nymo SH; Hulthe J; Muntendam P; McMurray JJ; Wikstrand J; Aukrust P Am Heart J; 2012 Dec; 164(6):878-83. PubMed ID: 23194488 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]